Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), <i>RAS</i> and <i>BRAF</i>...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/9/2350 |
| _version_ | 1797556870523650048 |
|---|---|
| author | Romain Cohen Thomas Pudlarz Jean-François Delattre Raphaël Colle Thierry André |
| author_facet | Romain Cohen Thomas Pudlarz Jean-François Delattre Raphaël Colle Thierry André |
| author_sort | Romain Cohen |
| collection | DOAJ |
| description | Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), <i>RAS</i> and <i>BRAF</i> mutations, <i>HER2</i> amplification or <i>NTRK</i> fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, <i>HER2</i>, <i>NTRK</i>). |
| first_indexed | 2024-03-10T17:08:07Z |
| format | Article |
| id | doaj.art-acd2471679d94bd99dadcfe46884a413 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T17:08:07Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-acd2471679d94bd99dadcfe46884a4132023-11-20T10:44:18ZengMDPI AGCancers2072-66942020-08-01129235010.3390/cancers12092350Molecular Targets for the Treatment of Metastatic Colorectal CancerRomain Cohen0Thomas Pudlarz1Jean-François Delattre2Raphaël Colle3Thierry André4Department of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, FranceDepartment of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, FranceDepartment of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, FranceDepartment of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, FranceDepartment of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, FranceOver the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), <i>RAS</i> and <i>BRAF</i> mutations, <i>HER2</i> amplification or <i>NTRK</i> fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, <i>HER2</i>, <i>NTRK</i>).https://www.mdpi.com/2072-6694/12/9/2350colorectal cancer<i>NTRK</i><i>HER2</i><i>BRAF</i>microsatellite instabilityctDNA |
| spellingShingle | Romain Cohen Thomas Pudlarz Jean-François Delattre Raphaël Colle Thierry André Molecular Targets for the Treatment of Metastatic Colorectal Cancer Cancers colorectal cancer <i>NTRK</i> <i>HER2</i> <i>BRAF</i> microsatellite instability ctDNA |
| title | Molecular Targets for the Treatment of Metastatic Colorectal Cancer |
| title_full | Molecular Targets for the Treatment of Metastatic Colorectal Cancer |
| title_fullStr | Molecular Targets for the Treatment of Metastatic Colorectal Cancer |
| title_full_unstemmed | Molecular Targets for the Treatment of Metastatic Colorectal Cancer |
| title_short | Molecular Targets for the Treatment of Metastatic Colorectal Cancer |
| title_sort | molecular targets for the treatment of metastatic colorectal cancer |
| topic | colorectal cancer <i>NTRK</i> <i>HER2</i> <i>BRAF</i> microsatellite instability ctDNA |
| url | https://www.mdpi.com/2072-6694/12/9/2350 |
| work_keys_str_mv | AT romaincohen moleculartargetsforthetreatmentofmetastaticcolorectalcancer AT thomaspudlarz moleculartargetsforthetreatmentofmetastaticcolorectalcancer AT jeanfrancoisdelattre moleculartargetsforthetreatmentofmetastaticcolorectalcancer AT raphaelcolle moleculartargetsforthetreatmentofmetastaticcolorectalcancer AT thierryandre moleculartargetsforthetreatmentofmetastaticcolorectalcancer |